Lundbeck Seattle Biopharmaceuticals

Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.

Lundbeck Seattle Biopharmaceuticals
FormerlyAlder Biopharmaceuticals
Company typeSubsidiary
Founded1 January 2004
2004 Edit this on Wikidata
Headquarters,
U.S.
ParentLundbeck
Websitehttps://www.lundbeck.com/us/about-us/lundbeck-in-the-us

In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million.[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]

As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4][5] The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.[6]

References

edit
  1. ^ "Alder BioPharmaceuticals stock flat after unexciting IPO". geekwire.com. 8 May 2014. Retrieved 24 August 2017.
  2. ^ "Deals this week: Onconova Therapeutics, Humorigin Biotechnology, Zosano Pharma". Drug Development Technology. Kable. 2 February 2018. Retrieved 3 February 2018.
  3. ^ "Alder Biopharmaceuticals Inc - Company Profile and News". Bloomberg.com. Retrieved 2019-05-21.
  4. ^ Kilgore, Tomi (2019-09-16). "Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal". Market Watch. Retrieved 2019-10-21.
  5. ^ staff, Seattle Times business (2019-09-16). "Alder BioPharma, Bothell developer of migraine-prevention drug, acquired for up to $2 billion". The Seattle Times. Retrieved 2020-06-18. {{cite web}}: |first= has generic name (help)
  6. ^ Podsada, Janice (August 5, 2020). "Bay Area bio-tech firm to open production plant in Bothell". The Everett Herald. Retrieved February 19, 2022.